Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group nucleosomal binding domain 2 pseudogene 4 (HMGN2P4) is a processed pseudogene in the human genome, related by sequence homology to the genuine gene HMGN2, which encodes a chromatin-associated protein involved in nucleosome binding and transcriptional regulation. Like other pseudogenes, HMGN2P4 does not encode a functional protein, and its biological roles—if any—remain largely uncharacterized. Although some pseudogenes modulate expression of their parent genes by acting as competing endogenous RNAs (ceRNAs), miRNA decoys, or regulators of mRNA stability, there are currently no specific publications documenting functional or pathological implications of HMGN2P4. It is not considered a druggable or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 4 (HMGN2P4).